Literature DB >> 1308114

Recombinant versus plasma-derived hepatitis B vaccine: comparison of immunogenicity in medical students.

J Möst1, C Larcher, W Vogetseder, W M Prodinger, H P Huemer, C F Ebenbichler, M P Dierich.   

Abstract

A group of 92 medical students were immunized with a commercial recombinant hepatitis B vaccine (Engerix B). Antibody responses were determined and compared with those to plasma-derived Pasteur vaccine, obtained in 1986. Antibody concentrations were significantly higher in the group given recombinant vaccine, therefore this vaccine has superior immunogenicity and probably confers extended duration of protection.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1308114     DOI： 10.1016/0264-410x(92)90507-g

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  4 in total

1.  24 year outcomes of hepatitis B vaccination in Hangzhou, China.

Authors:  Jian Du; Yuyang Xu; Jun Wang; Shijun Liu; Yan Liu; Xiaoping Zhang; Erping Xu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan.

Authors:  H-Y Hsu; M-H Chang; Y-H Ni; H-L Chen
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

4.  Comparison of long-term immunogenicity (23 years) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children.

Authors:  Qian Wu; Gui-hua Zhuang; Xue-liang Wang; Tie-jun Hou; Dimpy P Shah; Xiao-li Wei; Li-rong Wang; Min Zhang
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.